Cargando…

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis

Background Programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) have dramatically improved cancer therapy for many patients. Adverse kidney effects have been found to be an important complication but have unclear mechanisms. Methods We searched Embase, PubMed, and the Cochrane Library to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Han, Xu, Jinsheng, Bai, Yaling, Zhang, Shenglei, Cheng, Meijuan, Jin, Jingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068624/ https://www.ncbi.nlm.nih.gov/pubmed/33409896 http://dx.doi.org/10.1007/s10637-020-01039-5

Ejemplares similares

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
por: Carretero-González, Alberto, et al.
Publicado: (2018)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
por: Al-Showbaki, Laith, et al.
Publicado: (2021)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
por: Choi, Jin Wook, et al.
Publicado: (2020)

Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
por: Cona, Maria Silvia, et al.
Publicado: (2019)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771
por: Gray, Michael, et al.
Publicado: (2015)

Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer
por: Wu, Lipei, et al.
Publicado: (2022)

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
por: Zhang, Hao, et al.
Publicado: (2023)

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
por: Inoue, Takashi, et al.
Publicado: (2022)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1
por: NISHIBORI, Shoma, et al.
Publicado: (2023)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer
por: Yang, Hui, et al.
Publicado: (2020)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
por: Naing, Aung, et al.
Publicado: (2019)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
por: Sato, Hiro, et al.
Publicado: (2020)

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies
por: Al-Showbaki, Laith, et al.
Publicado: (2022)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3gg96f3qo74nrusa1n1vk9gadv